September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Twelve years incidence of late age-related macular degeneration in the Thessaloniki Eye Study
Author Affiliations & Notes
  • Panayiota Founti
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki , Greece
    Moorfields Eye Hospital, London, United Kingdom
  • Anne L Coleman
    Stein Eye Institute, University of California Los Angeles (UCLA), Los Angeles, California, United States
    Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles (UCLA), California, California, United States
  • M Roy Wilson
    Wayne State University, Detroit, Michigan, United States
  • Alon Harris
    Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Theofanis Pappas
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki , Greece
  • Fei Yu
    Stein Eye Institute, University of California Los Angeles (UCLA), Los Angeles, California, United States
    Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles (UCLA), Los Angeles, California, United States
  • Eleftherios Anastasopoulos
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki , Greece
  • Angeliki Salonikiou
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki , Greece
  • Archimidis Koskosas
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki , Greece
  • Fotis Topouzis
    Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki , Greece
  • Footnotes
    Commercial Relationships   Panayiota Founti, None; Anne Coleman, None; M Roy Wilson, None; Alon Harris, AdOM (I), AdOM (C), Biolight (C), Isama therapeutics (C), Nano Retina (C), Ono (C), Oxymap (I), Science Based Health (C), Stemnion Inc. (C); Theofanis Pappas, None; Fei Yu, None; Eleftherios Anastasopoulos, None; Angeliki Salonikiou, None; Archimidis Koskosas, None; Fotis Topouzis, Alcon (R), Alcon (C), Alcon (F), Allergan (C), Bausch & Lomb (C), Bayer (C), Humphrey Zeiss (C), Novartis (F), Novartis (C), Pfizer (F), Santen (R), Thea (F), Thea (C)
  • Footnotes
    Support  This research has been co‐financed by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) ‐ Research Funding Program: THALES. Investing in knowledge society through the European Social Fund.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 12. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Panayiota Founti, Anne L Coleman, M Roy Wilson, Alon Harris, Theofanis Pappas, Fei Yu, Eleftherios Anastasopoulos, Angeliki Salonikiou, Archimidis Koskosas, Fotis Topouzis; Twelve years incidence of late age-related macular degeneration in the Thessaloniki Eye Study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):12.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To determine incidence rates of late age-related macular degeneration (AMD), including geographic atrophy (GA) and neovascular AMD, in the Thessaloniki Eye Study (TES) population.

Methods : This is a population-based incidence study. A total of 2554 randomly selected, Caucasian subjects, ≥60 years old participated in the TES prevalence study between 1999 and 2002. Participants were re-invited to undergo a comprehensive ophthalmic examination during the incidence study between 2013 and 2015. Definitions for late AMD in the incidence study were the same as in the prevalence study (Topouzis F, et al. Prevalence of age-related macular degeneration in Greece: the Thessaloniki Eye Study. Am J Ophthalmol. 2006;142:1076-9).

Results : Among 2554 subjects who participated in the TES prevalence study, 1041 were deceased, 25 had moved and for 20 subjects no contact information was available. The remaining 1468 subjects for whom contact data were confirmed were deemed eligible to participate in the incidence study. All of the 1468 subjects were invited and 1092 were examined (participation rate 74.4%).
The mean age at baseline was 68.9 ± 4.6 years with 566 males (51.8%) and 526 (48.8%) females. The mean follow-up time was 11.6 ± 1.6 years.
Among the 1092 participants, 14 subjects had been already diagnosed with late AMD at baseline (6 subjects with neovascular AMD and 8 subjects with GA), leaving a total of 1078 participants at risk for late AMD in the incidence study. Among them, there were 55 incident cases of late AMD (21 males and 34 females, 38.18% and 61.82% respectively), corresponding to an incident rate of 5.4%. Among these 55 incident cases, 29 were GA and 26 were neovascular AMD, corresponding to incident rates of 2.7% and 2.4% respectively.

Conclusions : In the TES population the twelve year incident rate for late AMD was 5.4%, which appears to be higher than the 2 year late AMD incidence rate reported by Rotterdam when extrapolated to the 12-year incidence (Klaver CC, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42:2237-41).

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×